IAG, Image Analysis Group is comprised of Image Analysis, Ltd. (HQ: London, UK), Image Analysis, Inc. (HQ: Philadelphia, PA, USA) and Venture Partners. IAG is unique partner to life sciences companies. Our goal is to accelerate novel drug development by using the right analytical tools and modern trial infrastructure.
At IAG, we are committed to helping our biotech and pharma partners to efficiently develop novel life-changing medicines, by accelerating their R&D pipelines through advanced analytics, IAG’s technology solutions and imaging contract research services.
IAG’s foundation is in software development, use of Artificial Intelligence and data sciences applied to medical imaging.
Today, IAG leads the industry when it comes to optimizing clinical trial designs with imaging-based methodologies that can accelerate go / no-go efficacy decisions for emerging therapeutics and enrich patient selection in musculoskeletal, oncology, immunology, rheumatology, CNS and rare disease trials.
IAG’s proprietary platform DYNAMIKA, developed to maximize efficiencies of handling imaging data in multi-centre clinical trials is used by blue-chip pharmaceutical companies, CROs, biotechnology companies, and academics world-wide.
Smart use of novel approaches for central image review and our modern trial infrastructure ensure the speed and cost-effectiveness of phase I-VI trial execution, while delivering true insights about novel mechanisms of action and patients’ response, in real-time.
IAG’s teams within our three divisions – strategy, operations and bio-partnering together with our world-class Scientific Advisory Board closely work with our life science partners to address their goals of smart trial design, efficient execution and monetization of their assets through successful partnerships.
We are here to create successful partnerships and to see more patients cured with the drugs, that we can help you to develop.